New drug combo takes aim at brain lymphoma

NCT ID NCT03964090

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of six drugs (TEDDI-R) in 48 adults with aggressive B-cell lymphoma that has spread to the central nervous system. The goal is to see if this mix can control the cancer better than current treatments. Participants receive the drugs in 21-day cycles and are followed for up to 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: temozolomide, etoposide, doxil, dexamethasone, ibrutinib, and rituximab (TEDDI-R)
What this could lead to: If successful, this combination could offer a new treatment option for patients with aggressive lymphoma that has spread to the central nervous system, potentially improving disease control.
What could go wrong: This is a small, early-phase trial (48 participants) with no control group, so results may not apply broadly. The drug combination has significant side effects, including infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM LYMPHOMA SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.